• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

    10/29/24 4:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email

    TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.

    To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company's website.

    About Cronos

    Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

    Forward-looking Statements

    This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

    Cronos Contact

    Anna Shlimak

    Investor Relations

    Tel: (416) 504-0004

    [email protected]



    Primary Logo

    Get the next $CRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • When will Cronos Group Inc. hold its 2024 third quarter earnings conference call?

      Cronos Group Inc. will hold its third quarter earnings conference call on November 12, 2024, at 8:30 a.m. ET.

    • How can participants attend the Cronos Group earnings conference call?

      Participants can register for the conference call and webcast online at the Cronos Group's investor relations webpage.

    • What will Cronos' senior management discuss during the conference call?

      The conference call will include a discussion of the Company's financial results and will allow for questions from the investment community afterward.

    • What is the focus of Cronos Group in terms of its brand portfolio?

      Cronos Group is committed to building an iconic brand portfolio in the cannabinoid industry, with brands like Spinach, PEACE NATURALS, and Lord Jones.

    • What type of statements are included in the press release regarding Cronos Group's future intentions?

      The press release contains forward-looking statements that reflect the company's intention to grow its brand portfolio and develop new intellectual property.

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    1/27/2022$5.54 → $3.24Underperform → Hold
    Jefferies
    More analyst ratings